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Abstract In the field of so-called chronic daily headache,
it is not easy for migraine that worsens progressively until
it becomes daily or almost daily to find a precise and
universally recognized place within the current interna-
tional headache classification systems. In line with the
2006 revision of the second edition of the International
Classification of Headache Disorders (ICHD-2R), the cur-
rent prevailing opinion is that this headache type should be
named chronic migraine (CM) and be characterized by the
presence of at least 15 days of headache per month for at
least 3 consecutive months, with headache having the same
clinical features of migraine without aura for at least 8 of
those 15 days. Based on much evidence, though, a CM
with the above characteristics appears to be a heteroge-
neous entity and the obvious risk is that its definition may
be extended to include a variety of different clinical enti-
ties. A proposal is advanced to consider CM a subtype of
migraine without aura that is characterized by a high fre-
quency of attacks (10–20 days of headache per month for
at least 3 months) and is distinct from transformed
migraine (TM), which in turn should be included in the
classification as a complication of migraine. Therefore, CM
should be removed from its current coding position in the
ICHD-2 and be replaced by TM, which has more restrictive
diagnostic criteria (at least 20 days of headache per month
for at least 1 year, with no more than 5 consecutive days
free of symptoms; same clinical features of migraine
without aura for at least 10 of those 20 days).
Keywords Chronic migraine  Transformed migraine 
Chronic daily headache  Chronic headache  Headache 
Migraine
Introduction
The 1980s were a seminal period for the study of primary
headache, as they were characterized not only by a wealth
of investigational activity and significant progress in the
knowledge of the disease, but above all by an increasingly
rigorous approach from the scientific point of view.
The decade opened with the results of the Danish
studies [1, 2] on regional cerebral blood flow (rCBF) in
migraine—which was still named ‘‘classic’’ back then and
is now known as ‘‘with aura’’. These studies paved the
way for the trigeminovascular theory, which is still con-
sidered a good explanation for the underlying pathoge-
netic mechanisms of the disease. Then, at the close of the
decade came a number of accurate controlled trials that
demonstrated the efficacy of sumatriptan in the
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symptomatic treatment of migraine [3], leading to the
introduction of a new class of drugs that are still con-
sidered the therapy of choice for migraine attacks. In
between, there were two all-important steps: the joint
commitment from researchers of several countries to draw
up the first version of the International Headache Society
(IHS) classification, which was published in 1988 [4] and
represented a true cultural and practical turning point; and
the first demonstrations of investigators’ interest for those
migraine patients who over time experience a progressive
increase in the frequency of attacks until they develop a
so-called chronic daily headache (CDH) [5, 6].
Among headache experts, the debate on CDH has been
heated and controversial since the very beginning and is
not yet over. To sum up the question in a few words, we
can say that the issue revolved around two antithetic views.
On the one hand, there were those who thought that, in
the wide-ranging headache chapter, CDH was a group that
naturally included different subtypes—some of which still
undefined—but was nonetheless autonomous and therefore
should be considered, assessed and classified indepen-
dently of the other primary headache forms [6–8].
On the other hand, there were those who thought that
CDH was nothing but an entirely generic definition, a
hotchpotch containing a non-homogeneous group of dis-
parate headache forms that had already found their place in
the current classification systems: in their opinion, this was
a non diagnosis, or a diagnosis still waiting to be defined, if
not a diagnosis made by unskilled people [9, 10].
Both views were based on elements and remarks that
were worthy of the utmost respect. The former view was
more closely related to clinical practice, the latter view
paid more attention to formal aspects; the former view was
more critical of the current nosographic identification and
classification systems; the latter view reflected the con-
viction that the IHS classification has always been thor-
oughly exhaustive since its first 1988 edition [4].
In the next 20 years, the authors who originally
embraced either view continued to investigate the issue of
CDH in general and of its subtypes in particular; while
clinging to their initial beliefs, they were nonetheless
willing to pay attention to their counterpart’s opinions and
advances.
This intelligent, non-dogmatic approach led to very
important, albeit not yet conclusive, achievements.
We will first deal with the milestones that led to the
current state of knowledge on CDH in general and
chronic migraine in particular. The current official view
of the issue will be expounded with all relevant critical
points and a proposal will be advanced for changes and
adjustments to the classification of the main CDH sub-
chapter: the one about migraine that evolves unfavourably
over time.
Milestones to the current notions of CDH and chronic
migraine
Mathew et al. [5] in 1982 were the first to call attention to
the possibility that migraine may be transformed into daily
headache over time.
Five years later, the same group of researchers [6]
reported a case series of 630 CDH patients and attempted
to subdivide them into three different groups depending on
their headache type: ‘‘Type I starts as daily or near-daily
headache with no change in the severity and lacks
migrainous features; Type II starts as daily or near-daily
headaches with occasional more severe headache with
some migrainous features; Type III (transformed or evol-
utive migraine) starts as a clear-cut occasional episodic
migraine …. with increasing frequency over the next many
years….. evolving into chronic daily headaches’’. As many
as 489 of the 630 CDH patients of Mathew et al. (77.7%)
belonged to Type III, while only 57 (9.0%) and 84 (13.3%)
belonged to Type II and Type I, respectively. These authors
in 1987 were not yet talking about chronic tension-type
headache (CTTH), nor about new daily persistent headache
(NDPH), a form of primary headache first described just
1 year earlier by Vanast [11]. Both were still unknown
definitions, even though the two first CDH types could
seemingly be identified with these two headache forms.
However, back then they already suggested the term
‘‘transformed or evolutive migraine’’ for the third type.
Mathew [12] himself in 1993 definitely chose the name
‘‘transformed migraine’’ (TM), which he included in the
first true CDH classification, alongside CTTH and NDPH
(Table 1).
The following year, Silberstein, together with Lipton,
Solomon and Mathew again [13], proposed that hemicrania
continua (HC) should be added to these three forms and
that each of the four forms thus identified should be dis-
tinguished depending on the presence or absence of med-
ication overuse (Table 1). They also set precise diagnostic
criteria for each form. TM criteria are reported in Table 2.
In 1995, following the description of a broad case series
of CDH patients seen at the Parma and Pavia headache
centres in Italy, Manzoni et al. [14] first introduced the
name ‘‘chronic migraine’’ (CM), which they included,
alongside migraine with interparoxysmal headache (MIH),
within the migraine forms that evolve unfavourably over
time until they lose the typical symptom-free interval
between an attack and the next (Table 1). According to the
Italian authors, CM and MIH differentiate from each other
for the type of headache that sets in the originally free
intervals between attacks: while retaining the clinical fea-
tures of migraine in CM, in MIH this interval headache
loses its similarities to migraine: in some cases it has the
same features of tension-type headache, but in other cases
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it has undefined features and this prevents it from being
definitely included in the migraine or the tension-type
headache group.
The proposals introduced in the mid-1990s by the US
authors [13] and the Italian authors [14] differ from each
other in several respects. First, they use different approa-
ches to identify CDH entities: while Silberstein et al. [13]
adopt a more detailed and exhaustive classification that
includes also NDPH and HC, Manzoni et al. [14] prefer a
classification that takes into account only the forms most
frequently encountered in clinical practice. Secondly, and
more importantly, the differences between them concern:
(a) the terminology used to describe migraine forms that
evolve unfavourably over time (TM for Silberstein and CM
for Manzoni); (b) the temporal requirements for these
headache forms (presence of headache at least 15 days per
month for at least 1 month for Silberstein and at least
6 days per week for at least 1 year for Manzoni); and
(c) Manzoni et al.’s attempt to identify possible clinical
subtypes in the group of migraine forms evolving unfa-
vourably (CM and MIH with interval headache with or
without tension-type headache features).
If we browse the scientific CDH literature produced
from the mid-1990s to as late as 2006, we can see how
predominant Silberstein et al.’s systematization became.
Almost all studies conducted over this long period of time
and aimed at defining the epidemiological, pathogenetic
and therapeutic aspects of CDH basically followed Sil-
berstein et al.’s classification [13], both in terms of head-
ache forms included in the classification, and in terms of
their respective diagnostic criteria and the terminology
proposed to give an official name to each form. In this
connection, it is worth noting that there was a general and
widespread acceptance of the TM name.
On the other hand, we are sorry to say that the 2004
edition of the International Classification of Headache
Disorders classification (ICHD-2) [15] only partially—and
not always appropriately—integrated those considerations
in its final changes over the 1988 first edition of the IHS
classification [4].
In the first place, the ICHD-2 [15] editors did not deem
it advisable to devote a separate chapter to CDH within
their classification—which, all things considered, is actu-
ally a decision we can agree on.
Secondly, of the four different CDH forms identified by
Silberstein et al. [13] (Table 1), only one, CTTH, was
already included in the 1988 first edition of the IHS clas-
sification [4] and then again in the 2004 ICHD-2 classifi-
cation [15]. Two other forms, HC and NDPH, did not
appear in the IHS classification [4] but were included in the
ICHD-2 classification [15], where they were coded to
Group 4 ‘‘Other primary headaches’’. The last of Silber-
stein et al.’s [13] CDH forms, TM, was not recognized as
such in the ICHD-2 [15], which however included for the
first time CM and its diagnostic criteria, coded to 1.5.1 as a
complication of migraine (Table 3). Thus, with respect to
Table 1 Classifications of chronic daily headache introduced in the
mid-1990s
Mathew [12]
1. Transformed migraine
2. Chronic tension-type headache
3. New daily persistent headache
Silberstein et al. [13]
1. Transformed migraine
1.1 With medication overuse
1.2 Without medication overuse
2. Chronic tension-type headache
2.1 With medication overuse
2.2 Without medication overuse
3. New daily persistent headache
3.1 With medication overuse
3.2 Without medication overuse
4. Hemicrania continua
4.1 With medication overuse
4.2 Without medication overuse
Manzoni et al. [14]
1. Evolution of migraine
1.1 Migraine with interparoxysmal headache
1.1.1 Migraine with interparoxysmal headache fulfilling
the criteria for chronic tension-type headache
1.1.2 Migraine with interparoxysmal headache not fulfilling
the criteria for chronic tension-type headache
1.2 Chronic migraine
2. Chronic tension-type headache
Table 2 Diagnostic criteria for transformed migraine by Silberstein
et al. [13]
A. Daily or almost daily ([15 days/month) head pain for
[1 month
B. Average headache duration of [4 h day (if untreated)
C. At least 1 of the following:
1. History of episodic migraine meeting any HIS criteria 1.1–1.6
2. History of increasing headache frequency with decreasing
severity of migrainous features over at least 3 months
3. Headache at some time meets HIS migraine criteria 1.1–1.6
other than duration
D. Does not meet criteria for new daily persistent headache or
hemicrania continua
E. At least 1 of the following:
1. There is no suggestion of one of the disorders listed in groups
5–11
2. Such a disorder is suggested, but it is ruled out by appropriate
investigations
3. Such a disorder is present, but first migraine attacks do not
occur in close temporal relation to the disorder
J Headache Pain (2011) 12:585–592 587
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the most important and certainly most frequent of all CDH
forms, i.e. migraine evolving unfavourably over time, the
ICHD-2 [15] eventually retained the CM name, originally
proposed by Manzoni et al. [14], but with diagnostic cri-
teria ([15 days per month for at least 3 months) that are
very different from those suggested by the Italian authors
(at least 6 day per week for at least 1 year). In addition, the
ICHD-2 [15] ignored the MIH proposed by the same
authors [14]. The result is that only for some of the patients
affected by this clinical entity—precisely those with an
interval headache resembling tension-type headache—can
the ICHD-2 [15] provide a diagnosis, but even so it would
be a dual diagnosis, of migraine without aura and of ten-
sion-type headache. MIH patients with an interval head-
ache not resembling either migraine or tension-type
headache remain unclassified.
With respect to Silberstein et al.’s classification [13], the
ICHD-2 classification [15] neither recognizes the TM def-
inition nor agrees with its diagnostic criteria (Tables 2, 3).
Additionally, the ICHD-2 [15] does not envisage, either for
CM or even for CTTH, HC and NDPH, a differentiation
based on the presence or absence of medication overuse,
because it prefers to retain Medication-overuse headache as
an autonomous clinical entity (coded to 8.2 of the 2004
classification), much as the 1988 IHS classification [4] had
already done.
As defined by the diagnostic criteria of the ICHD-2
classification [15], CM seems: (a) to resemble more a high-
frequency migraine than a migraine evolving over time to a
daily or near-daily form and eventually losing some, and in
certain cases, many of its typical migraine features, such as
unilateral and/or throbbing pain and/or nausea and vomit-
ing as accompanying symptoms; (b) to be scarcely relevant
to actual clinical practice, because a patient with more than
15 days of headache per month is highly unlikely to use
symptomatic drugs for less than 10–15 days per month.
Since its inclusion in the ICHD-2 classification [15],
then, CM has always appeared as an ambiguous clinical
entity and one that would not be of much use either for
clinical practice or research.
Bigal et al. [16] in the US tried to re-classify 638 CDH
patients seen over a period of 20 years at the New England
Medical Center for Headache in Stamford, Connecticut. By
strictly applying the diagnostic criteria of the ICHD-2 [15],
they managed to establish a diagnosis of CM only in nine
cases. In contrast, using the diagnostic criteria proposed by
Silberstein et al. [13], the number of patients that in the
same case series could be classified as suffering from TM
without medication overuse would be as high as 158.
Therefore, the authors concluded that CM diagnosis, as
defined and formally applied in the ICHD-2 [15], does not
offer any considerable benefit to the CDH diagnostic issue.
Another major shortcoming of the ICHD-2 classification
[15] is that, as was clearly demonstrated in the same
analysis by Bigal et al. [16], most CDH patients receive
multiple diagnoses, in several cases as many as four or five,
including some that are only probable. Since the very
introduction of the ICHD-2 [15] in 2004, then, it has been
clear that the diagnostic criteria of CM needed to be
changed.
Current official stance about CM: merits and critical
issues
Even the Committee that worked them out was aware of
this problem and new criteria were formulated as a result
(ICHD-2R) [17]. Today, these criteria (Table 3) are con-
sidered standard reference and, according to Olesen, all of
them could be integrated in the future ICHD-3 classifica-
tion [18, 19].
This is undoubtedly a significant step forward. The new
criteria [17] are much more relevant to actual clinical
practice than the previous ones of the ICHD-2 classifica-
tion [15] and may provide a good starting point to get to a
better understanding of this complex and all-important
chapter of headaches [20–22].
Table 3 Diagnostic criteria for chronic migraine by the ICHD-2
(2004) and by the ICHD-2R (2006)
ICHD-2 (2004)
A. Headache fulfilling criteria C and D for migraine without aura
on C15 days per month for [3 months
B. Not attributed to another disorder
ICHD-2R (2006)
A. Headache (tension-type and/or migraine) on C15 days per
month for C3 months
B. Occurring in a patient who has had at least five attacks
fulfilling criteria for 1.1 Migraine without aura
C. On C8 days per month for C3 months headache has fulfilled
C.1 and/or C.2 below; that is, has fulfilled criteria for pain and
associated symptoms of migraine without aura:
1. Has at least two of a–d:
a. Unilateral location
b. Pulsating quality
c. Moderate or severe pain intensity
d. Aggravation by or causing avoidance of routine physical
activity (e.g., walking or climbing stairs)
And at least one of a or b below:
a. Nausea and/or vomiting
b. Photophobia and phonophobia
2. Treated and relieved by triptan(s) or ergot before the
expected development of C.1 above
D. No medication overuse and not attributed to another causative
disorder
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Nevertheless, a few questions remain to be solved and
these basically concern two aspects that the headache cli-
nician knows well and the headache researcher cannot
underestimate.
The first major question is that a severity gradient exists
in CM, as defined in the ICHD-2R classification [17]
diagnostic criteria, and it is so wide-ranging as to carry the
risk of including exceedingly different cases under the
single group of CM [23]. Patients who for 3 months have
had 8 days of migraine and 7 days of tension-type head-
ache per month have almost nothing to do with patients
who have suffered from migraine-like headache every day
for years. The former have a good chance of improving, if
adequately treated; the latter generally do not respond well
to standard treatments and require a special, customized
therapeutic approach. In other words, the minimum time
limits set in the ICHD-2R [17] for diagnosis of CM
(15 days per month for 3 months) appear to be too short to
allow inclusion of CM itself among complications of
migraine. These might actually be cases of migraine with a
transiently high frequency or of a transient association of
medium-frequency migraine and medium-frequency ten-
sion-type headache, as can often be seen in the natural
history of migraine. However, none of these cases would
represent a true complication of migraine. Creating a single
loose-net subchapter of headaches, as would be the case
with CM according to the ICHD-2R [17], will likely be of
no use either to the clinician or to the researcher or even the
drug trial investigator. Indeed, it could ultimately jeopar-
dize the key goal of all those who are concerned with the
issue, i.e. providing both basic and clinical research with a
reliable instrument that can be effectively used to collect
homogeneous and well-defined case series. If the tool we
are using does not allow an adequate selection of the case
series under study, the results obtained—whether from
epidemiological surveys, pathogenetic investigations or
drug trials—will be misleading and the effort made to
achieve them useless [24–29].
The second major question is the problem of symp-
tomatic medication overuse, which affects most patients
with CM [30–35]. As the IHS classification [4] before it,
the ICHD-2 classification [15] also includes Medication-
overuse headache in Group 8 (‘‘Headache attributed to a
substance or its withdrawal’’). The ICHD-2 [15] diagnostic
criteria were revised twice in the last few years and those
that are currently recognized as valid (ICHD-2R) (Table 4)
for diagnosis of Medication-overuse headache no longer
require that headache resolve or revert to its previous
patterns within 2 months after discontinuation of the
overused medication [17]. Thus, according to the ICHD-2R
classification [17], a patient with a form of migraine that
has worsened over the years or has become complicated
evolving into daily or near daily, with daily or near-daily
use of symptomatic drugs, should have a dual diagnosis:
Medication-overuse headache and Probable CM. Apart
from the drawbacks of multiple diagnoses, it is difficult to
see a patient with CM who will not use drugs to block, or at
least relieve pain, and if the headache recurs at least
15 days per month—as must happen for the diagnosis of
CM to be established—this patient will likely report
medication overuse as a consequence, if not necessarily as
a cause. Instead of a dual diagnosis of Medication-overuse
headache and Probable CM, would not a single diagnosis
of CM with medication overuse be preferable in such a
patient until he/she is freed from the overused drugs?
The uncertainties about Medication-overuse headache
are also related to the lack of specific scientific data on
the role that the individual symptomatic drugs taken by
migraineurs might play on the underlying course of the
disease, if overused.
As things stand now, we cannot but agree with what was
recently stated by Bigal et al.: ‘‘The ultimate question that
needs to be discussed by the scientific community is not
how to better classify migraine overuse headache, but if
migraine overuse headache should exist as a single entity
or is more appropriately viewed as a risk factor’’ [36].
A new proposal for classification of CM
The next edition of the ICHD classification (ICHD-3), due
out by the end of 2012, will certainly introduce some
changes to CM as defined in the ICHD-2 classification [15]
(Table 3).
It may be that for CM the ICHD-3 will merely replace
the much criticized diagnostic criteria of the ICHD-2 [15]
with the more acceptable ones proposed by the ICHD-2R
[17] (Table 3). This would certainly be a significant step
forward over the ICHD-2 [15], but a few questions remain
unsolved.
The term ‘‘chronic migraine’’ seems ambiguous and
inaccurate. Olesen himself [37] criticized the use of the
Table 4 Diagnostic criteria for Medication-overuse headache by the
ICHD-2R (2006)
A. Headache present on C15 days/month
B. Regular overuse for [3 months of one or more acute/
symptomatic treatment drugs as defined under subforms
1. Ergotamine, triptans, opioids, or combination analgesic
medications on C10 days/month on a regular basis for
[3 months
2. Simple analgesics or any combination of ergotamine, triptans,
analgesic opioids on C15 days/month on a regular basis for
[3 months without overuse of any single class alone
C. Headache has developed or markedly worsened during
medication overuse
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adjective ‘‘chronic’’, which, as was reported in a recent
article by Seshia et al. [38], is given three different
meanings in the ICHD-2 [15]. The term ‘‘transformed
migraine’’ is to be preferred, because it is less ambiguous
and more indicative of the type of patients we are referring
to [12, 13, 39–41].
Even though we avoid use of the adjective ‘‘chronic’’, in
order to establish a diagnosis of TM we nonetheless have to
set a minimum period of time for the duration of this daily
or near-daily headache pattern. The 3 month period gen-
erally taken as reference until now seems too short and
carries the inherent risk of considering TM as a form of
migraine that merely undergoes an entirely transient
worsening. A 1 year period seems more appropriate
[42, 43].
The same applies to the other temporal parameter, which
must define and therefore better specify the vague expres-
sion ‘‘daily or near-daily’’ originally used by Mathew et al.
[5, 6]. Quantifying this daily or near-daily parameter as
C15 days appears an oversimplification. In order to avoid
too loose a categorization, a more accurate statement
would be C20 days/month, adding also that there are never
[5 headache-free consecutive days [44].
Then, there is the big question of Medication-overuse
headache. From the IHS classification [4] to the ICHD-2
[15] and ICHD-2R [17] classifications, the question has
become increasingly confused [33, 39–42]. The addition of
triptans, the addition of overuse from other symptomatic
drugs, the addition of the limits of 10 days/month for
overuse from certain drugs and 15 days/month for overuse
from other drugs, the addition and then the removal of the
criterion that required improvement within 2 months (!)
from withdrawal of medication, the addition and then the
removal of a description of certain headache features for
some types of overuse… All these tentative changes clearly
indicate that we are still a long way from knowing this
topic well, because literature reports are still much too
scarce. As is currently categorized in the ICHD-2 [15] or
proposed in the ICHD-2R [17], Medication-overuse head-
ache today is a largely arbitrary entity and its very exis-
tence appears questionable for certain subtypes. The only
sure data we have are those about ergotamine, caffeine and
combined medications containing barbiturates or codeine
and, partly, triptans. Waiting for future specific studies to
yield more reliable results than are available today and help
clarify whether Medication-overuse headache should be
considered less an autonomous entity than a complication
of migraine [45], at the current state of knowledge perhaps
we should better take a more cautious approach to this
chapter.
A basic reason that could explain why, in spite of the
efforts made by so many authors for so many years, we
have not yet come to share a common systematization for
the classification of migraine that evolves unfavourably, is
that international classifications—the IHS of 1988 [4] and
the ICHD-2 of 2004 [15]—are typically classifications of
headache attacks, providing a ‘‘snapshot’’ of a headache
attack at a given moment. For primary headaches at least,
they are not and do not purport to be classifications of
disorders or of patients. This approach certainly has merits
and advantages and such classifications have become
indispensable tools for epidemiological, pathophysiologi-
cal and therapeutic research. However, they are not suitable
for headache forms such as CM or TM, in which what
matters most is the patient’s history, and not a snapshot of
his/her headache, which can only be blurred and confused.
Hopefully, in the future we will be able and willing to
engage in the preparation of a classification of headache
syndromes that may combine all current international
headache classifications. This is an ambitious and difficult
project, which will require several years to complete, but
could allow an adequate and correct categorization of
patients with CDH.
Waiting for this goal to be achieved, based on the cur-
rent state of knowledge and on what was previously dis-
cussed and expounded in this paper, we think it reasonable
to formulate a simple and practical proposal, which can be
broken down as follows:
(a) differentiation of migraine without aura based on
frequency of attacks, with the addition of a third-digit
level (Table 5);
(b) shifting of CM from its current coding position in the
ICHD-2 and the ICHD-2R among migraine compli-
cations to a different coding position as a high-
frequency subtype of migraine without aura; CM,
coded to 1.1.3 would then represent an evolution
stage in the natural chronicization course of migraine;
(c) introduction of precise temporal parameters among the
diagnostic criteria for the three migraine without aura
subtypes (infrequent, frequent and chronic) (Table 6);
(d) inclusion of TM among the complications of
migraine: TM should be coded to 1.5.1 replacing
Table 5 Proposed revision of the ICHD-2 for migraine
1.1 Migraine without aura
1.1.1 Infrequent migraine
1.1.2 Frequent migraine
1.1.3 Chronic migraine
1.1.3.1 With medication overuse
1.1.3.2 Without medication overuse
1.5 Complications of migraine
1.5.1 Transformed migraine
1.5.1.1 With medication overuse
1.5.1.2 Without medication overuse
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CM (Table 5) and its diagnostic criteria should be
different from those listed in the ICHD-2R [17] only
in as far as frequency and duration are concerned
([20 days/month for C1 year and never with [5
headache-free consecutive days) (Table 6);
(e) differentiation of TM at the fourth-digit level depend-
ing on the presence or absence of symptomatic
medication overuse (Table 5) (i.e. use for [20 days/
month) regardless of whether overuse played any role
in the worsening of the headache;
(f) shifting of Medication-overuse headache to the Appen-
dix with alternative diagnostic criteria to be defined.
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